Subscribe
shutterstock_1197728128_photobyphm-jpg
photobyphm / Shutterstock.com
14 February 2019Big Pharma

EU court rejects Bayer’s heart-related TM

Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EU General Court dismisses Bayer’s Aspirin trademark appeal
25 October 2018   Trademarks covering Bayer’s branded Aspirin were at the centre of an appeal dismissed by the EU General Court yesterday.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
EU General Court dismisses Bayer’s Aspirin trademark appeal
25 October 2018   Trademarks covering Bayer’s branded Aspirin were at the centre of an appeal dismissed by the EU General Court yesterday.

More on this story

Big Pharma
EU General Court dismisses Bayer’s Aspirin trademark appeal
25 October 2018   Trademarks covering Bayer’s branded Aspirin were at the centre of an appeal dismissed by the EU General Court yesterday.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB